EUR1.4m contract win with US firm

RNS Number : 6509W
Venn Life Sciences Holdings PLC
11 November 2014
 



 

Venn Life Sciences Holdings Plc

("Venn" or the "Company" or the "Group")

 

€1.4million contract with US firm for European Trial

 

Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the signing of an agreement worth over €1.4 million to conduct a European wide Phase II study for a US based company.

 

The deal comes on the back of multiple significant contract signings for Venn this year and sees the Company expanding its US customer base. Including this contract, Venn has announced new business wins totaling €8m in the past six months. This volume of business represents a major step change for Venn and justifies the significant investment in personnel and infrastructure in the past 18 months.  

 

Speaking about the agreement, Venn CEO, Tony Richardson stated: "The recent project wins demonstrate that our strategy of expanding our core services, our locations and our teams is coming to fruition for us as a company, and for our shareholders and our stakeholders. We now have a solid book of profitable contracts and a healthy pipeline of opportunities, which gives us confidence that we will deliver further growth in 2015."

 

 

Enquiries:

Venn Life Sciences Holdings Plc

www.vennlifesciences.com

Tony Richardson, Chief Executive Officer

Tel: +353 154 99 341

Orla Mc Guinness, Marketing Manager

 

Tel: +594 694410116

Zeus Capital (Nominated Adviser and Broker)

 

Ross Andrews/Andrew Jones (Corporate Finance)

Tel: +44 (0)161 831 1512

Dominic Wilson (Institutional Sales)

Tel: +44 (0)20 7533 7721

 

 

Walbrook PR Ltd

Tel: +44 (0)20 7933 8780 or venn@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

About Venn Life Sciences Limited:

Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCURUBRSSAAAAA

Companies

Hvivo (HVO)
UK 100